NDA 022580 · Vivus LLC
Qsymia
Phentermine Hydrochloride, Topiramate · Oral
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Jul 17, 2012
Approved uses
3
Original approval plus efficacy supplements
Registered trials
73
8 Phase 3, 5 recruiting
FAERS reports
6,540
887 serious, 16 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 18, 2026.
Phentermine and topiramate extended-release capsules are indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbid condition Limitations of Use The effect of phentermine and topiramate extended-release capsules on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of phentermine and topiramate extended-release capsules in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. Phentermine and topiramate extended-release capsules are a combination of phentermine, a sympathomimetic amine anorectic, and topiramate, indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity ( 1 ). Adults with overweight in the presence of at least one weight-related comorbid condition ( 1 ). Limitations of Use: The effect of phentermine and topiramate extended-release capsules on cardiovascular morbidity and mortality has not been established ( 1 ). The safety and effectiveness of phentermine and topiramate extended-release capsules in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established ( 1 ).
Mechanism: Phentermine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and d/l-amphetamine). Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics." The effect of phentermine on weight reduction and long-term maintenance of body weight is likely mediated by release of catecholamines in the hypothalamus, resulting in reduced appetite and decreased food consumption, but other metabolic effects may also be involved. The exact mechanism of action is not known. The precise mechanism of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 13, 2024 Supplement 25 · Efficacy LabelLetter
- Jun 24, 2022 Supplement 21 · Efficacy LetterLabel
- Jul 17, 2012 Original approval · Type 4 - New Combination LabelReviewOther
4 products under this application
- QSYMIA · PHENTERMINE HYDROCHLORIDE EQ 15MG BASE; TOPIRAMATE 92MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- QSYMIA · PHENTERMINE HYDROCHLORIDE EQ 7.5MG BASE; TOPIRAMATE 46MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- QSYMIA · PHENTERMINE HYDROCHLORIDE EQ 11.25MG BASE; TOPIRAMATE 69MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- QSYMIA · PHENTERMINE HYDROCHLORIDE EQ 3.75MG BASE; TOPIRAMATE 23MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Phentermine" as an intervention, any sponsor and status, largest first.
- A Toolbox Approach to Obesity Treatment in Primary CarePivotal-lookingCompleted
Denver Health and Hospital AuthorityAcademic, hospital or other
NCT01922934 · 4,730 participants · Start Jan 2014 · Primary completion Aug 2016
Drug: Obesity pharmacotherapy · For: Obesity
Sites: Denver, Colorado
- Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid ConditionsPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00553787 · 2,487 participants · Start Nov 2007 · Primary completion Jun 2009
Drug: VI-0521; VI-0521 and 1 more · For: Obesity; Type 2 Diabetes
Sites: Birmingham, Alabama; Ridgefield, Connecticut; New York, New York · 6 sites in all
- Study of VI-0521 Compared to Placebo in Treatment of Obesity in AdultsPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00554216 · 1,267 participants · Start Nov 2007 · Primary completion May 2009
Drug: VI-0521; VI-0521 and 1 more · For: Obesity
Sites: San Diego, California; Ridgefield, Connecticut; Durham, North Carolina · 5 sites in all
- Long-term Effectiveness of the Antiobesity Medication PhenterminePivotal-lookingCompleted
Wake Forest University Health SciencesAcademic, hospital or other
NCT05176626 · 870 participants · Start Jun 30, 2022 · Primary completion Sep 30, 2026
Drug: Phentermine Hydrochloride 8 MG · For: Obesity; Obesity; Drug; Lifestyle, Healthy
Sites: Los Angeles, California; Saint Louis Park, Minnesota; Winston-Salem, North Carolina · 4 sites in all
- A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in AdultsPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00563368 · 756 participants · Start Dec 2007 · Primary completion Sep 2008
Drug: VI-0521; VI-0521 and 5 more · For: Obesity
Sites: Durham, North Carolina; Philadelphia, Pennsylvania
- A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)Pivotal-lookingCompleted
VIVUS LLCIndustry
NCT00796367 · 676 participants · Start Dec 2008 · Primary completion Jun 2010
Drug: VI-0521; Placebo and 1 more · For: Obesity
- Intermittent Phentermine for Obesity and Body CompositionPivotal-lookingCompleted
OSCAR MANUEL TORRES FALCONAcademic, hospital or other
NCT07870668 · 600 participants · Start Mar 1, 2024 · Primary completion Jan 15, 2026
Drug: Phentermine 15 MG; Phentermine 30 mg and 1 more · For: Obesity & Overweight
Sites: León, Mexico
- A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese SubjectsPivotal-lookingCompleted
VIVUS LLCIndustry
NCT05215418 · 565 participants · Start Jan 25, 2022 · Primary completion Apr 11, 2023
Drug: VI-0521; Phentermine and 1 more · For: Blood Pressure
Sites: Anniston, Alabama; Mobile, Alabama; Lincoln, California · 28 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache408
- paraesthesia349
- dry mouth312
- insomnia311
- dizziness297
- weight increased295
- feeling abnormal263
- inappropriate schedule of product administration257
- fatigue232
- constipation228
- nausea224
- anxiety212
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 2 |
| 2013 | 107 |
| 2014 | 302 |
| 2015 | 398 |
| 2016 | 366 |
| 2017 | 271 |
| 2018 | 183 |
| 2019 | 162 |
| 2020 | 226 |
| 2021 | 262 |
| 2022 | 366 |
| 2023 | 794 |
| 2024 | 1,134 |
| 2025 | 1,186 |
| 2026 | 781 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Wang Y, Hao Q, et al. · Lancet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.
McGowan B, Ciudin A, Baker JL, et al. · Nat Med 2025 · Systematic Review, Network Meta-Analysis
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
Nong K, Shi Q, Xie X, et al. · BMJ 2026 · Systematic Review, Network Meta-Analysis
- Pharmacotherapy for obesity.
Ioannides-Demos LL, Proietto J, McNeil JJ · Drugs 2005 · Meta-Analysis, Review
- Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Elkind-Hirsch KE, Chappell N, Seidemann E, et al. · J Clin Endocrinol Metab 2021 · Equivalence Trial, Randomized Controlled Trial
- Obesity in adults.
Delaet D, Schauer D · BMJ Clin Evid 2011 · Systematic Review
Sponsor: Vivus LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.